Экономические аспекты терапии фосфатбиндерами


Н.А. Михайлова

Кафедра нефрологии и гемодиализа ГБОУ ДПО РМАПО Минздрава России, Москва
Обсуждаются экономические аспекты терапии фосфатбиндерами пациентов с хронической болезнью почек, в т. ч. с точки зрения улучшения сердечно-сосудистого прогноза, уменьшения частоты и продолжительности госпитализаций.

Литература



  1. Mahon A. Epidemiology and classification of chronic kidney disease and management of diabetic nephropathy // Eur Endocr Rev. – 2006: 33–36.

  2. Foley R.N., Parfrey P.S. Cardiovascular disease and mortality in ESRD // J Nephrol. – 1998; 2: 239–245.

  3. Levey A.S., Andreoly S.P., DuBose T. et al. Chronic kidney disease: common, harmful and treatable: World Kidney Day 2007 // Pediatr Nephrol. – 2007;22:321–325.

  4. ERA-EDTA Daily congress news. – Issue 2/may 19, 2013. Р. 14.

  5. De Vecchi A.F., Dratwa M., Wiedemann M.E. Healthcare systems and end-stage renal disease (ESRD) therapies--an international review: costs and reimbursement/funding of ESRD therapies // Nephrol. Dial. Transplant. – 1999;14 Suppl 6:31–41.

  6. National Institute for Clinical Excellence. Final Appraisal Determination: The clinica and cost-effectiveness of home compared with hospital haemodialysis for patients with end-stage renal failure. http://www.nice.org.uk. 2007

  7. Михайлова Н.А. Значение фосфатбиндеров в лечении минеральных и костных нарушений при хронической болезни почек с учетом центральной роли нарушения гомеостаза фосфора в их формировании: обзор литературы // Клиническая нефрология. – 2013;1:64–70.

  8. White C.A., Jaffey J., Magner P. Cost of applying the K/DOQI guidelines for bone metabolism and disease to a cohort of chronic hemodialysis patients // Kidney Int. – 2007;71:312–317.

  9. Savica V., Calo L.A., Monardo P. et al. Phosphate binders and management of hyperphosphataemia in end-stage renal disease // Nephrol. Dial. Transplant. – 2006;21: 2065–2068.

  10. Rayner H.C., Pisoni R.L., Bommer J. et al. Mortality and hospitalization in haemodialysis patients in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS) // Nephrol. Dial. Transplant. – 2004;19:108–120.

  11. A.C. Covic. Magnesium – beneficial effects over & above phosphate binding: ERA-EDTA Congress, Prague, 2011, 25 June, Industry Sponsored Simposium.

  12. Qunibi W.Y., Hootkins R.E., McDowell L.L. et al. Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study) // Kidney Int. – 2004;65: 1914–1926.

  13. De Francisco A.L.M., Leidig M., Covic A.C. et al. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability // Nephrol Dial Transplant. – 2010;25:3707–3717.

  14. Deuber H.J. Long-term efficacy and safety of an oral phosphate binder containing both calcium and magnesium carbonate in hemodialysis patients // Nieren- und Hochdruckkrankheiten. – 2004;33:403–408.

  15. Huybrechts K.F., Caro J.J., Wilson D.A. et al. Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis // Value. Health. – 2005;8:549–561.

  16. Qunibi W. Y., Moustafa M., Kessler P. et al. Coronary artery calcification (CAC) in Hemodialysis Patients (HDP): preliminary results fromteh Calcium Acetate Renagel Evaluation-2 (CARE-2) Study. American Society of Nephrology. – 2006.

  17. Brophy D.F., Wallace J.F., Kennedy D.T. et al. Cost-effectiveness of sevelamer versus calcium carbonate plus atorvastatin to reduce LDL in patients with chronic renal insufficiency with dyslipidemia and hyperphosphatemia // Pharmacotherapy. – 2000;20:950–957.

  18. Navaneethan S.D., Palmer S.C., Craig J.C. et al. Benefits and Harms of Phosphate Binders in CKD: A Systematic Review of Randomized Controlled Trials // Am J Kidney Dis. – 2009;54:619–637.

  19. Tonelli M., Pannu N., Manns B. Oral Phosphate Binders in Patients with Kidney Failure // N Engl J Med. – 2010;362:1312–1324.

  20. Tzanakis I.P., Wei M. Magnesium carbonate for phosphate control in patients on hemodialysis: A randomized controlled trial // Int Urol Nephrol. – 2008;40:193–201.

  21. Spiegel D.M., Farmer B. Long-term effects of magnesium carbonate on coronary artery calcification and bone mineral density in hemodialysis patients: A pilot study // Hemodial Int. – 2009;13:453–459.

  22. Manns B., Stevens L., Miskulin D. et al. Systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States // Kidney Int. – 2004;66:1239–1247.

  23. Peter W. St., Liu J., Fan Q. et al. DCOR Study: Assessing impact of sevelamer vs calcium binders on hospitalization & morbidity in hemodialysis patients using CMS data: Poster presentation. 2006.

  24. Bellucci G., Alessandri M., Buracchi P. et al. Serum Magnesium concentration and serum prathormone in hemodialysis patients // Ital J Mineral Electrolyte Metab. – 1998;12:77–79.

  25. Suki W., Zabaneh R., Cangiano J. et al. A Prospective Randomized Trial Assessing the Impact on Outcomes of Sevelamer in Dialysis Patients: The DCOR Trial. – American Society of Nephrology. – 2005.

  26. Block G.A., Raggi P., Bellasi A. et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients // Kidney Int. – 2007;71:438–441.

  27. Young E.W. Dialysis Outcomes & Practice Patterns Study (DOPPS II, 2002–2004) // J.Am.Soc Nephrol. – 16.2005.

  28. Manns B., Klarenbach S., Lee H. et al. Economic evaluation of sevelamer in patients with end-stage renal disease // Nephrol.Dial.Transplant. – 2007.

  29. Suki W.N., Zabaneh R., Cangiano J.L. et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients // Kidney Int. – 2007.

  30. Peter W. St., Liu J., Fan Q. et al. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data // Am J Kidney Dis. – 2008;51:445–454.

  31. Peter W. St., Liu J., Fan Q. et al. Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare & Medicaid services data // Clin J Am Soc Nephrol. – 2009;12:1954–1961.

  32. Cangialose C., Yeh Y., Pelham R. et al. The economics of phosphate binders in renal dialysis: a two stage strategy for managing hyperphosphatemia // Value Health. – 2003;6:198.

  33. Brennan A., Akehurst R., Davis S. et al. The cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in patients with end-stage renal disease // Value Health. – 2007;10:32–41.

  34. Рlagemann T., Prenzler A., Mittendorf T. Considerations about the effectiveness and cost effectiveness of therapies in the treatment of hyperphosphataemia // Health Economics Review. – 2011;1:1–14.


Об авторах / Для корреспонденции


Михайлова Н.А. – доцент кафедры нефрологии и гемодиализа ГБОУ ДПО РМАПО Минздрава России, к.м.н.


Похожие статьи


Бионика Медиа